Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav
The inspection was carried out between May 26, 2025 and May 31, 2025
The inspection was carried out between May 26, 2025 and May 31, 2025
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Subscribe To Our Newsletter & Stay Updated